Approvable Letter Issued By FDA For Arxxant™ (ruboxistaurin Mesylate) For Diabetic Retinopathy

... Eli Lilly and Company announced today that it received an approvable letter from the U.S. Food and Drug Administration (FDA) for ruboxistaurin mesylate (proposed trade name Arxxant™, pronounced, ark-ZONT), its investigational oral therapy being studied for treatment of diabetic retinopathy (DR), a diabetic eye disease. [click link for full article] ...